Vaccination with Mycobacterium bovis bacille Calmette-Guérin (BCG) is widely used to reduce the risk of childhood tuberculosis and has been reported to have efficacy against two other mycobacterial diseases, leprosy and Buruli ulcer caused by M. ulcerans (Mu). Studies in experimental models have also shown some efficacy against infection caused by Mu. In mice, most studies use the C57BL/6 strain that is known to develop good cell-mediated protective immunity. We hypothesized that there may be differences in vaccination efficacy between C57BL/6 and the less resistant BALB/c strain.
We evaluated BCG vaccine efficacy against challenge with ∼3×105 M. ulcerans in the right hind footpad using three strains: initially, the Australian type strain, designated Mu1617, then, a Malaysian strain, Mu1615, and a recent Ghanaian isolate, Mu1059. The latter two strains both produce mycolactone while the Australian strain has lost that capacity. CFU of both BCG and Mu and splenocyte cytokine production were determined at intervals after infection. Time to footpad swelling was assessed weekly.
BCG injection induced visible scars in 95.5% of BALB/c mice but only 43.4% of C57BL/6 mice. BCG persisted at higher levels in spleens of BALB/c than C57BL/6 mice. Vaccination delayed swelling and reduced Mu CFU in BALB/c mice, regardless of challenge strain. However, vaccination was only protective against Mu1615 and Mu1617 in C57BL/6 mice. Possible correlates of the better protection of BALB/c mice included 1) the near universal development of BCG scars in these mice compared to less frequent and smaller scars observed in C57BL/6 mice and 2) the induction of sustained cytokine, e.g., IL17, production as detected in the spleens of BALB/c mice whereas cytokine production was significantly reduced, e.g., IL17, or transient, e.g., Ifnγ, in the spleens of C57BL/6 mice.
The efficacy of BCG against M. ulcerans, in particular, and possibly mycobacteria in general, may vary due to differences in both host and pathogen.
Vaccination with Mycobacterium bovis bacille Calmette-Guérin (BCG) is used to reduce the risk of childhood tuberculosis and is reported to have efficacy against two other diseases also caused by mycobacteria, leprosy and Buruli ulcer caused by M. ulcerans. We hypothesized that there may be differences in the effectiveness of BCG vaccination in different mouse strains. We vaccinated two mouse strains with BCG eight weeks before infection with three different strains of M. ulcerans. Two of the bacterial strains make a toxin that is critical for Buruli ulcer disease and the third does not. We observed the progression of disease in vaccinated and mock-vaccinated mice and also evaluated the immune response of the mice. We found that the BALB/c mice respond to BCG vaccination with prominent scars, a vigorous immune response, and delayed or no manifestations of M. ulcerans infection. C57BL/6 mice, on the other hand, usually do not have vaccination scars, make a relatively short-lived and/or weaker immune response, and all show disease at the site of M. ulcerans infection. We conclude that the efficacy of BCG against M. ulcerans, and possibly other diseases, depends on the nature of the host and of the infecting strain of the bacteria.
Citation: Converse PJ, Almeida DV, Nuermberger EL, Grosset JH (2011) BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Negl Trop Dis 5(3): e985. doi:10.1371/journal.pntd.0000985
Editor: Craig R. Roy, Yale University School of Medicine, United States of America
Received: June 25, 2010; Accepted: February 14, 2011; Published: March 15, 2011
Copyright: © 2011 Converse et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors are grateful for the funding of this work that was provided by the Fondation Raoul Follereau (http://www.raoul-follereau.org/) and by NIH-NIAID (http://www.niaid.nih.gov) R01-AI.082612. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
BCG vaccination is widely practiced around the world, primarily to protect against tuberculosis. BCG is a safe vaccine but its efficacy against tuberculosis varies by geographical region and possibly by BCG strain due to mutations related to culturing practices in multiple laboratories for many decades. The current consensus is that it protects against disseminated tuberculosis in young children but that it has limited value in protecting against adult pulmonary tuberculosis, perhaps affording 50% protection at best . On the other hand, large trials  have shown that even where BCG has no discernible benefit against tuberculosis, it does protect against leprosy, a disease caused by another mycobacterium, M. leprae. Against yet another mycobacterial disease, known as Mycobacterium ulcerans disease or Buruli Ulcer (BU), retrospective and prospective studies have found that BCG vaccination appears to have protective efficacy for only up to 6 months but there may be longer term protection against severe forms of BU, such as osteomyelitis , , , , . A case report indicated that the Th1 type immunity following BCG vaccination changed to a Th2 type after the onset of BU , . Our preliminary investigation of a toxin-negative Mu strain and studies by others suggested differences in host response between C57BL/6 and BALB/c mice , , , and therefore, studies in mice might help identify the timing and nature of the switch and allow testing of alternative ways to maintain protective immunity.
Mycobacterium ulcerans disease was first described in the medical literature in 1948 in Australian patients . The disease still occurs there, primarily in coastal areas visited by vacationers. In contrast, many more cases have been documented to occur in Africa, initially in the Congo  and Uganda , and then, increasingly in West Africa where it primarily affects impoverished people in rural riverine and swampy areas , , . The exact mode of transmission is controversial. Bug bites are frequently but not universally recalled. M. ulcerans grows slowly at ∼30–32 °C. It was the first mycobacterium shown to produce a toxin, an immunosuppressive macrolide, named mycolactone , , . Toxin-producing colonies have a yellowish color. The toxin is encoded by the pksA gene, located on a giant plasmid , , . The toxin destroys subcutaneous fat cells, apparently by both apoptotic and necrotic mechanisms , , . Both guinea pigs and mice have been used to model the disease and study the organism , , , . In mice injected in the hind footpad, there is gradual, infection-dose-dependent swelling that becomes severe before the onset of ulceration and, if allowed, may progress to foot and limb loss and death , .
Here, we vaccinated BALB/c and C57BL/6 mice with BCG (Pasteur) and, after 8 weeks, challenged vaccinated and unvaccinated mice with either M. ulcerans 1059 (Mu1059), a recent clinical isolate from Ghana, or with Mu1615, a strain originally isolated from Malaysia in the 1960s. Both strains produce mycolactone and both cause a gradually severe swelling in mouse footpads in unvaccinated mice.
Materials and Methods
M. ulcerans 1059 (Mu1059, a recent clinical isolate from Ghana) and M. ulcerans 1615 (Mu1615, an isolate originally obtained from a patient in Malaysia in the 1960s,  were kindly provided by Dr. Pamela Small, University of Tennessee. M. ulcerans 1617 (Mu1617, the type strain isolated from a patient in Australia in the 1940s, ) was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Thin layer chromatographic analysis and cytotoxicity assays of ethanolic extracts showed that Mu1059 and Mu1615, but not Mu1617, produce mycolactone and kill macrophages and fibroblasts (, and see Fig. S3). All three strains were passaged in mouse footpads before use in these studies. The bacilli were harvested from swollen footpads at the grade 3 level, i.e., swelling with inflammation of the footpad and leg .
Female BALB/c and C57BL/6 mice, aged 4–6 weeks, obtained from Charles River (Wilmington, MA), were vaccinated subcutaneously with 5.8×104 CFU of M. bovis BCG, Pasteur strain, in 0.2 ml or with the diluent (Middlebrook 7H9, also 0.2 ml) as a sham manipulation, 8 weeks before challenge with M. ulcerans.
Challenge and CFU analysis
Mice were inoculated in the right hind footpad with approximately 3×105 in 0.03 ml of Mu1059, Mu1615, or Mu1617. At different time points after challenge, mice were sacrificed and footpad tissue was harvested, minced with fine scissors , suspended in 2.0 ml PBS, serially diluted, and plated for CFU analysis on Middlebrook selective 7H11 plates (Becton-Dickinson, Sparks, MD). Mice were evaluated for footpad swelling weekly using an established scoring system  with grade 1 showing footpad swelling, grade 2 swelling with inflammation, and grade 3 swelling and inflammation of the entire foot . Time to grade 1 swelling was assessed by Kaplan-Meier analysis. All animal procedures were conducted according to relevant national and international guidelines. The study was conducted adhering to the Johns Hopkins University guidelines for animal husbandry and was approved by the Johns Hopkins Animal Care and Use Committee, protocols MO08M240 and MO05M226.
After BCG or sham vaccination, spleens were harvested from mice, placed in 2.5 ml RPMI 1640 (Mediatech, Herndon, VA) and passed through a 70 µm cell strainer (BD Falcon 352350) into a centrifuge tube. From the suspension, 120 µl was added to 1.88 ml of RPMI containing 5% fetal bovine serum and 1% penicillin (100 U/ml) and streptomycin (100 µg/ml). From this suspension 100 µl was added to triplicate wells of a 96 well plate (Costar 3595, Corning, NY) containing 10 µl of culture filtrate protein of Mtb H37Rv (CFP, [10 µg/ml]) or Mtb antigen 85 (Ag85), also at 10 µg/ml, both supplied by Colorado State University TB Vaccine Testing and Research Materials Contract (NIH-NIAID N01-AI-40091), or with Concanavalin A (ConA, Sigma, [2 µg/ml]). The cells were incubated at 37 °C for 48 hours before harvesting, pooling, and freezing at −70 °C of triplicate 50 µl supernatants. The remainder of the suspension was used to enumerate BCG CFU.
A 23-plex Luminex assay (Biorad, Hercules, CA) was used to detect 4 Th1 (IL2, IL12b/p40, IL12p70, and Ifnγ), 4 Th2 (IL4, IL5, IL10, and IL13), and 4 proinflammatory cytokines (IL1α, IL1β, IL6, and Tnfα) as well as IL17, IL9, 6 chemokines (Cxcl1, Ccl2, Ccl3, Ccl4, Ccl5, and Ccl11), and 3 colony stimulating factors (IL3, Csf2, and Csf3). Using aliquots from the same supernatants, Tgfβ was detected using Milliplex beads (Millipore, Billerica, MA).
Comparisons were made by the log-rank test for time-to-grade 1 swelling and by 2-way ANOVA for log10 transformed CFU counts and cytokine levels.
BCG vaccination produces scars more frequently in BALB/c than in C57BL/6 mice
Nearly all BALB/c mice developed visible scars at the site of vaccination in the flank (Fig. 1) but such scars occurred less frequently and were smaller in C57BL/6 mice. This observation was assessed and noted for each mouse 13 weeks after vaccination and 5 weeks after M. ulcerans challenge. In all, 95.5% of BALB/c mice but only 43.4% of C57BL/6 mice had scars after BCG vaccination. No sham-vaccinated mice had scars.
Scars were less frequently seen in C57BL/6 mice and tended to be smaller. The pictured mouse was vaccinated 10 weeks previously and had been challenged with M. ulcerans 2 weeks previously in the right hind footpad.
After subcutaneous vaccination, BCG multiplies in spleen and survives longer in BALB/c mice
C57BL/6 mice are considered to be more resistant than BALB/c mice to intracellular infections with mycobacteria or leishmania species , . Consistent with these observations we found that after subcutaneous M. bovis BCG vaccination, BALB/c mice have higher levels of BCG detectable in the spleen than do C57BL/6 mice (Fig. 2 A, B, C). In addition, the levels persisted longer in BALB/c mice. The number of BCG CFU in the spleen tended to be higher in M. ulcerans-challenged C57BL/6 compared to unchallenged mice (Fig. 2 B and C) whereas there was no difference between challenged and unchallenged BALB/c mice.
Variability is greater in the C57BL/6 mice. At week 8, mice were challenged with M. ulcerans. By week 25, no BCG colonies could be detected in the C57BL/6 mice (A, C). (N = 3, except at week 25 where N = 2; one of two comparable experiments shown). At week 14 (B), BCG CFU appeared to be higher in C57BL/6 mice challenged with M. ulcerans. (C) The one C57BL/6 mouse available at week 25 after vaccination and 17 weeks after M. ulcerans challenge did have detectable BCG in the spleen.
M. ulcerans infection is established at comparable levels in BALB/c and C57BL/6 mice with all 3 bacterial strains
Mice were inoculated with freshly isolated suspensions containing ∼10 AFB/high-power microscopic field or 2.4–3×105 M. ulcerans in a volume of ∼0.03 ml in the right hind footpad, resulting in an implantation of ∼3.1–3.2 log10 of the Australian type strain, Mu1617 on day 1 (Fig. 3A). As reported by others (e.g., ) there is a lag phase with little or no increase in CFU during the first 2 weeks after challenge, followed by a logarithmic increase accompanied by footpad swelling by week 5 to 6 when the CFU counts reach 105 or higher. For example at week 2 after infection, we detected from ∼3–3.5 log10 M. ulcerans CFU in the mouse footpads infected with Mu1059 or Mu1615, independent of BCG vaccination status (data not shown).
A) CFU counts of the Mu1617 strain of M. ulcerans are comparable between C57BL/6 and BALB/c mice and with the mycolactone-producing Ghanaian strain, Mu1059 (not shown) regardless of BCG vaccination status. M. ulcerans CFU at day 28 are significantly lower in vaccinated BALB/c mice (**, p<0.01). B) and C): Mice that show a protective response to BCG vaccination have reduced M. ulcerans CFU after the onset of swelling (week 5 or 6) in unprotected, i.e., unvaccinated, mice.
BCG vaccination prevents multiplication of M. ulcerans better in BALB/c than in C57BL/6 mice
At week 6, after the onset of swelling in the sham-vaccinated mice, marked differences in M. ulcerans CFU counts were observed between BCG-vaccinated and unvaccinated (i.e., sham) BALB/c mice regardless of the infecting M. ulcerans strain (Mu1617, p<0.01, Mu 1059, p<0.001, or Mu1615, p<0.001, Figure 3). In C57BL/6 mice BCG vaccination did not result in a reduction in Mu1617 (Fig. 3A) or Mu1059 CFU (Fig. 3B) but did lead to a significant (p<0.01) reduction in M. ulcerans 1615 CFU (Fig. 3C) in the footpads of mice.
BCG vaccination delays time to footpad swelling in a M. ulcerans strain- and mouse strain-dependent manner
In unvaccinated BALB/c and C57BL/6 mice, the median time to grade 1 or higher footpad swelling was ∼5–6 weeks following infection with either of the toxin-producing strains (Fig. 4A and 4B) whereas it was 6.5 weeks in C57BL/6 mice and 16 weeks in BALB/c mice infected with the non-toxin-producing Mu1617 strain (Fig. 4C). All unvaccinated BALB/c and C57BL/6 mice developed footpad swelling except for 37% of BALB/c mice challenged with the Mu1617 strain.
BCG-mediated protection against swelling was greatest in BALB/c mice, regardless of M. ulcerans strain. Significant protection was also observed in C57BL/6 mice against the toxin-producing Malaysian strain, Mu1615 (B), and the non-toxin-producing Australian type strain, Mu1617 (C), but negligible protection was observed with the Ghanaian strain, Mu1059 (A). It is noteworthy that swelling occurred after infection with the non-toxin-producing Mu1617 strain (C) but that the onset of swelling was delayed even in unvaccinated BALB/c mice.
In BCG vaccinated BALB/c mice, the median time to swelling was >26 weeks in mice challenged with the Mu1059 Ghanaian strain (Fig. 4A) and 14 weeks with the Mu1615 Malaysian strain (Fig. 4B). Only 23% of vaccinated BALB/c mice developed swelling by week 36 after infection with the toxin free, Mu1617 Australian strain (Fig. 4C). Remarkably, approximately 25%, 50, or 75% of, vaccinated BALB/c mice infected with Mu1615, Mu1059, and Mu1617, respectively, never developed swelling. In addition, some appeared to self-heal with a regression of the swelling.
In contrast, the effect of BCG vaccination on median time to swelling in C57BL/6 mice varied from a delay of only 1 week in mice challenged with the Mu1059 strain (Fig. 4A) to a delay of 7 weeks in mice challenged with the Mu1615 and Mu1617 strains (Fig. 4B and 4C). All vaccinated C57BL/6 mice eventually developed swelling regardless of the challenge strain. Taken together, these results suggest that vaccine efficacy varies according to both the mouse strain and the M. ulcerans strain that were tested.
BCG vaccine efficacy correlates with BCG scar formation and with sustained cytokine production in response to mycobacterial antigens
At different times after vaccination, splenocytes were assessed for the ability to produce cytokines after restimulation with CFP or Ag85 of Mtb as well as Concanavalin A. The responses to Ag85 correlated very well with those to CFP. Because we tested more time points with CFP, we report, for the sake of simplicity, only those results. Similar results for cytokine production were observed after challenge with either Mu1615 or Mu1059 and, therefore, those data are combined.
The proinflammatory cytokines IL1α and IL1β were produced at identical levels and rates over the first 3 weeks after BCG vaccination in both mouse strains. Thereafter, production increased markedly in BALB/c but decreased in C57BL/6 mice at week 7. Production declined after challenge with M. ulcerans in both mouse strains when tested 8 weeks after BCG vaccination and one week after challenge. Two weeks after challenge, IL1 could not be detected in supernatants of C57BL/6 splenocytes stimulated with CFP (Fig. S1). The same pattern was observed for Tnfα (Fig. 5 A) and IL6 (Fig. 5E), except that the former was somewhat higher in C57BL/6 mice and the latter was higher in BALB/c mice. The differences at 3 weeks were not statistically significant.
Representative proinflammatory (A), Th1 (B), and Th2 (C) cytokines are shown. IL17 production is shown in Panel D. IL6, required for the generation of Th17 cells, is shown in panel E. Tgfβ, required for the generation of both Th17 and regulatory T (Treg) cells, production is shown in panel F. Graphs of other cytokines (Fig. S1) and also chemokines (Fig. S2) are available in Supplementary Materials.
The same kinetics of expression was observed for Th1 cytokines Ifnγ, IL2, IL12β, and IL12 p70 (Fig. S1). The peak at week 3 was higher for Ifnγ (Fig. 5B) and IL12β in C57BL/6 than in BALB/c mice; however, the differences were not statistically significant by 2-way ANOVA. IL12p70 was undetectable in C57BL/6 mice even before M. ulcerans challenge. Both Ifnγ and IL12p70 were undetectable 2 weeks after M. ulcerans challenge in both mouse strains.
Again the same kinetics pattern of sustained cytokine production in BALB/c mice but a peak in production at week 3 in C57BL/6 mice was observed for the Th2 cytokines IL4 (Fig. 5C), IL5, IL10, and IL13 (Fig. S1).
The pattern and the level of IL17 (Fig. 5D) production in response to CFP were markedly different between the two mouse strains. At week 3 the mean IL17 concentrations, in pg/ml, were 84±41 (range, 40–166) for BALB/c mice but 13±6 (range, 3–21) for C57BL/6 mice. At week 7 the concentrations were 2703±487 for BALB/c mice and 26±9 for C57BL/6 mice. After M. ulcerans challenge, IL17 was almost undetectable one week later in C57BL/6 mice whereas in BALB/c mice levels only declined to 705±203 and 67±13 in the two weeks after challenge. Among the factors required for the generation of Th17cells are IL6 and Tgfβ. As noted above, IL6 (Fig. 5E) levels were initially somewhat, though not significantly, higher in BALB/c than in C57BL/6 mice and, as with other cytokines, continued to increase in the BALB/c mice while declining in the C57BL/6 mice. The pattern for Tgfβ (Fig. 5F) was different from the other cytokines. Values were 2.5-fold higher at day 1, 3.2-fold lower at 3 weeks but again slightly higher at 7 weeks in BALB/c mice compared to C57BL/6 mice, although the differences were not statistically different. Tgfβ values also remained higher after M. ulcerans challenge in BALB/c mice but dropped precipitously in C57BL/6 mice. The results for Tgfβ could be consistent with the cytokine helping to drive, through the Rorγt transcription factor, a Th17 response in BALB/c mice while inducing a regulatory T cell (Treg) response, through the Foxp3 transcription factor, in C57BL/6 mice in which cytokine production was consistently down modulated after week 3. Taken together, the data suggest that the strong IL17 response in BALB/c mice compared to C57BL/6 mice correlates with BCG vaccine-mediated protection against M. ulcerans-induced footpad swelling and the reduction in M. ulcerans CFU detectable in BALB/c footpads.
BCG vaccination protects BALB/c mice better than C57BL/6 mice from the consequences of M. ulcerans infection. In the case of infection with the Mu1059 isolate from Ghana, C57BL/6 mice were essentially not protected at all whereas most BALB/c remained swelling free. In general, BALB/c mice make a stronger and more sustained cytokine response than do C57BL/6 mice. The most salient difference in cytokine production between the two mouse strains was the IL17 response. IL17 is known to be associated with protection against extracellular fungi and bacteria .
Others have also observed differential production of IL17 between C57BL/6 and BALB/c mouse strains . In contrast to our findings of an association between high levels of IL17 and BCG-induced protection from M. ulcerans disease, Lopez Kostka found that BALB/c mice produced “excessive” levels of IL17, as well as Th2 cytokines, and are more susceptible to cutaneous leishmaniasis after infection with L. major . In the leishmania model, C57BL/6 mice have a strong Th1 response but produce little IL17. In this model, killing of the organism occurs following Ifnγ production and macrophage activation with elaboration of nitric oxide. BCG, on the other hand, induces granuloma formation that may help contain mycobacteria. Very recently, Okamoto Yoshida et al. reported that mice lacking IL17, in a C57BL/6 background, fail to produce granulomas after pulmonary BCG infection . Whether subcutaneous BCG vaccination promotes granuloma formation in footpads and protection against M. ulcerans infection requires further investigation.
Our findings in BALB/c mice are consistent with those of Coutanceau et al.  who also observed a >3 log10 reduction in Mu1615 CFU at the site of infection in mice vaccinated subcutaneously with BCG Pasteur (Fig. 3C). The results here extend the data to C57BL/6 mice in which there was also a 3.26 log10 reduction in Mu1615 CFU at 6 weeks after challenge. An earlier study  found that in intravenously BCG-vaccinated C57BL/6 mice challenged with M. ulcerans strain 5150 from the Congo, there was only a 1.35–1.85 log10 reduction in the footpad CFU counts 7 weeks after challenge. We likewise saw a reduction of only 0.88 log10 CFU in vaccinated C57BL/6 mice challenged with the Ghanaian Mu1059 strain. However, vaccinated BALB/c mice challenged with Mu1059 showed a 4.32 log10 reduction in CFU. These data strongly support the idea that there are host differences in the ability to be protected by BCG from M. ulcerans infection as well as marked differences in the protection conferred against different strains of M. ulcerans.
In addition to counting M. ulcerans CFU, we assessed the ability of BCG vaccination to prevent footpad swelling, a clinically observable consequence of M. ulcerans infection in mice. BCG vaccination delayed the onset of footpad swelling in both BALB/c and C57BL/6 mice. However, the delay was greater in BALB/c mice, regardless of the challenge strain and C57BL/6 mice showed only a 1-week delay in swelling when challenged with the Ghanaian Mu1059 strain. These findings support the differences found in CFU and also tend to confirm the difference in host susceptibility to M. ulcerans noted parenthetically by others .
Differential susceptibility to mycobacterial infection in mice has been the subject of numerous studies. BALB/c and C57BL/6 mice have very similar survival rates after aerosol infection with M. tuberculosis. Both strains are markedly resistant compared to CBA, DBA/2, C3H, and 129/SvJ when challenged by the intravenous or aerosol routes. Interestingly, the distinction was overcome by increasing the i.v. challenge dose . This study was followed up by evaluating the ability of BCG vaccination to protect BALB/c and DBA/2 (both having the same MHC type) against an intravenous challenge with M. tuberculosis. For both strains there was a ∼10-fold reduction in the number of CFU in the lung 80 days after challenge. However, at this time, there was also a 100-fold difference in the number of CFU in the lungs of the immunized BALB/c and DBA/2 mice. In addition, the DBA/2 mice also had extensive necrotic lesions whereas the BALB/c lesions were more compact and epithelioid like . Similar findings were obtained when comparing vaccinated C57BL/6 mice and the susceptible strains, DBA/2 and CBA/J . Other studies have linked differential susceptibility to matrix metalloproteinases such as Mmp9 . Hence, the finding of a difference in the susceptibility of different mouse strains to mycobacteria is not novel but the difference in susceptibility of BALB/c and C57BL/6 mice, both resistant to M. tuberculosis, to M. ulcerans has not been shown before nor, to our knowledge, has the difference in the ability of BCG vaccination to protect these different mouse strains been examined before.
The importance of IL17 may be due to the fact that the intracellular phase is relatively brief after M. ulcerans infection due to toxin-mediated killing of phagocytic cells whereas, in mice, M. tuberculosis infection remains intracellular throughout the course of infection (unpublished observations and ). Studies in progress indicate that at week 2 after infection with a mycolactone-producing strain, Mu1615, the organisms are still largely intracellular. By week 3, the infection is predominantly extracellular in BALB/c mice, presumably due to the destruction of phagocytes by mycolactone. BCG vaccination may promote IL17 production, particularly in this mouse strain, and enable resistance against extracellular organisms. In contrast, C57BL/6 mice, infected with Mu1617, which does not produce mycolactone, have abundant organisms that appear to be intracellular, even at 4 weeks after infection.
The results of this study suggest that vaccination with BCG may protect some hosts more effectively than others against M. ulcerans infection or disease. In addition, the protection may depend on the strain of M. ulcerans prevalent in a given community. While the benefit of BCG vaccination may be variable, we also found no evidence of vaccination leading to exacerbated disease in this model.
Proinflammatory, Th1, and Th2 cytokine production after BCG vaccination before and after M. ulcerans challenge.
(0.04 MB DOC)
Chemokine production after BCG vaccination before and after M. ulcerans challenge.
(0.03 MB DOC)
Thin layer chromatography analysis shows that the Ghanaian (Mu1059) and Malaysian (Mu1615) strain produce mycolactone, but the Australian type strain (Mu1617) does not.
(4.46 MB TIF)
Conceived and designed the experiments: PJC DVA ELN JHG. Performed the experiments: PJC DVA. Analyzed the data: PJC. Wrote the paper: PJC ELN JHG.
- 1. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271: 698–702.
- 2. Ponnighaus JM, Fine PE, Sterne JA, Wilson RJ, Msosa E, et al. (1992) Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 339: 636–639.
- 3. Nackers F, Dramaix M, Johnson RC, Zinsou C, Robert A, et al. (2006) BCG vaccine effectiveness against Buruli Ulcer: a case-control study in Benin. Am J Trop Med Hyg 75: 768–774.
- 4. Portaels F, Aguiar J, Debacker M, Guedenon A, Steunou C, et al. (2004) Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 72: 62–65.
- 5. Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, et al. (2002) Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol 9: 1389–1391.
- 6. Smith PG, Revill WD, Lukwago E, Rykushin YP (1976) The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 70: 449–457.
- 7. Uganda Buruli Group (1969) BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1: 111–115.
- 8. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM (2002) Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 70: 5562–5567.
- 9. Gooding TM, Johnson PDR, Campbell DE, Hayman JA, Hartland EL, et al. (2001) Immune Response to Infection with Mycobacterium ulcerans. Infect Immun 69: 1704–1707.
- 10. Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, et al. (2006) Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes and Infection 8: 2075–2081.
- 11. Tanghe A, Adnet P-Y, Gartner T, Huygen K (2007) A booster vaccination with M. bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun:. pp. IAI.01622–01606.
- 12. Tanghe A, Content J, Van Vooren J-P, Portaels F, Huygen K (2001) Protective Efficacy of a DNA Vaccine Encoding Antigen 85A from Mycobacterium bovis BCG against Buruli Ulcer. Infect Immun 69: 5403–5411.
- 13. MacCallum P, Tolhurst JC, Buckle G, Sissons HA (1948) A new mycobacterial infection in man. J Pathol Bacteriol 60: 93–122.
- 14. Janssens PG, Quertinmont MJ, Sieniawski J, Gatti F (1959) Necrotic tropical ulcers and mycobacterial causative agents. Trop Geogr Med 11: 293–312.
- 15. Clancey JK, Dodge OG, Lunn HF, Oduori ML (1961) Mycobacterial skin ulcers in Uganda. Lancet 2: 951–954.
- 16. Asiedu K, Hayman J (2000) Epidemiology. In: Asiedu K, Scherpbier R, Raviglione M, editors. Buruli ulcer: Mycobacterium ulcerans infection. Geneva: World Health Organization.
- 17. World Health Organization (1997) WHO joins battle against a new emerging disease, Buruli ulcer. Geneva: World Health Organization. Press Release WHO/88 Press Release WHO/ 88:
- 18. World Health Organization (2003) Buruli ulcer disease. Weekly Epidemiological Record 78: 163–168.
- 19. Connor DH, Lunn HF (1965) Mycobacterium ulcerans infection (with comments on pathogenesis). Int J Lepr 33:
- 20. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854–857.
- 21. Read JK, Heggie CM, Meyers WM, Connor DH (1974) Cytotoxic activity of Mycobacterium ulcerans. Infect Immun 9: 1114–1122.
- 22. Stinear TP, Hong H, Frigui W, Pryor MJ, Brosch R, et al. (2005) Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J Bacteriol 187: 1668–1676.
- 23. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345–1349.
- 24. Stinear TP, Pryor MJ, Porter JL, Cole ST (2005) Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiology 151: 683–692.
- 25. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans Induces Persistent Inflammatory Responses in Mice. Infect Immun 73: 6299–6310.
- 26. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977–987.
- 27. Walsh DS, Meyers WM, Portaels F, Lane JE, Mongkolsirichaikul D, et al. (2005) High rates of apoptosis in human Mycobacterium ulcerans culture-positive Buruli ulcer skin lesions. Am J Trop Med Hyg 73: 410–415.
- 28. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005) Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cellular Microbiology 7: 1295–1304.
- 29. Fenner F (1956) The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc 73: 650–673.
- 30. Krieg RE, Hockmeyer WT, Connor DH (1974) Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch Dermatol 110: 783–788.
- 31. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45: 3109–3112.
- 32. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367–2372.
- 33. Pettit JHS, Marchette NJ, Rees RJW (1966) Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia. British Journal of Dermatology 78: 187–197.
- 34. Zhang T, Li S-Y, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56–61.
- 35. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193–3196.
- 36. Shepard CC (1967) A kinetic method for the study of the activity of drugs against Mycobacterium leprae. Int J Lepr 35: 429–436.
- 37. Lecoeur HF, Lagrange PH, Truffot-Pernot C, Gheorghiu M, Grosset J (1989) Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 76: 458–462.
- 38. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, et al. (2009) IL-17 Promotes Progression of Cutaneous Leishmaniasis in Susceptible Mice. J Immunol 182: 3039–3046.
- 39. Ortiz RH, Leon DA, Estevez HO, Martin A, Herrera JL, et al. (2009) Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clinical & Experimental Immunology 157: 271–281.
- 40. O'Quinn DB, Palmer MT, Lee YK, Weaver CT (2008) Emergence of the Th17 pathway and its role in host defense. Adv Immunol 99: 115–163.
- 41. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, et al. (2010) Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184: 4414–4422.
- 42. Medina E, North RJ (1998) Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93: 270–274.
- 43. Medina E, North RJ (1999) Genetically susceptible mice remain proportionally more susceptible to tuberculosis after vaccination. Immunology 96: 16–21.
- 44. Gruppo V, Turner OC, Orme IM, Turner J (2002) Reduced up-regulation of memory and adhesion/integrin molecules in susceptible mice and poor expression of immunity to pulmonary tuberculosis. Microbiology 148: 2959–2966.
- 45. Taylor JL, Hattle JM, Dreitz SA, Troudt JM, Izzo LS, et al. (2006) Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 74: 6135–6144.
- 46. Rhoades ER, Frank AA, Orme IM (1997) Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tubercle and Lung Disease 78: 57–66.